Molecular oncogenesis of chondrosarcoma: impact for targeted treatment

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Bone chondrosarcoma, especially unresectable or metastatic, carries a poor prognosis.
• Chondrosarcomas exhibit general resistance to conventional chemotherapy and radiotherapy.
• Limited treatment options necessitate exploration of novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in characterizing molecular pathways in chondrosarcoma oncogenesis.
• To identify potential molecular targets for improving the prognosis of advanced chondrosarcoma.
• To discuss the clinical implications of identified genetic alterations and targeted therapies.

Main Methods:

• Review of current literature on molecular pathways and genetic alterations in chondrosarcoma.
• Analysis of recent findings in oncogenic pathway characterization.
• Evaluation of ongoing clinical trials for targeted therapies in chondrosarcoma.

Main Results:

• Key oncogenic pathways identified include isocitrate dehydrogenase mutations, hedgehog signaling, retinoblastoma protein, p53 pathways, apoptosis, and tyrosine kinases.
• These specific molecular alterations represent potential targets for clinical intervention.
• Despite identified targets, clinical trial results for targeted therapies have been largely disappointing due to small patient cohorts in this orphan disease.

Conclusions:

• Classifying druggable targets is crucial for improving chondrosarcoma patient prognosis.
• Further therapeutic intervention studies based on preclinical findings are essential.
• Advancing targeted therapy research is critical for overcoming treatment resistance and improving outcomes in advanced chondrosarcoma.